Sandbox:Gunnam: Difference between revisions
No edit summary |
|||
Line 32: | Line 32: | ||
*Less commonly Patients with [[hypertension]] and [[dyslipidemia]] are also associated with developing NAFLD | *Less commonly Patients with [[hypertension]] and [[dyslipidemia]] are also associated with developing NAFLD | ||
* | |||
===Other Common Causes are :=== | |||
*Medications like Tamoxifen ,corticosteriods , methotrxate | |||
*Viral Hepatitis. | |||
*Rapid weight loss. | |||
*Malnutrition. | |||
Revision as of 15:38, 16 November 2017
Nonalcoholic fatty liver disease
- Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
Nonalcoholic fatty liver disease [NAFLD] is due to the deposition of extra fat in liver cells that is not caused by alcohol. It is normal for the liver to contain some fat. However, when there is more than 5 -10 percent of the liver’s weight is fat, then it is called a fatty liver (steatosis).NAFLD is marked by inflammation that can progress to irreversible damage.NAFLD is similar to the damage caused by alcohol consumption in most of the cases. It is estimated that in united states approximately 80 to 100 million people are affected with NAFLD. NAFLD most commonly affects people in the age group 2-19 and 40-50 years.It is most commonly seen in Hispanic population when compared to Caucasian and African American populations
Historical Perspective
- NAFLD is relatively new concept first introduced in 1980.
- Based on histology it is classified into the non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).NAFL mostly considered as a benign condition but recent studies show it can progress to NASH up to 44%. The more severe form of NAFLD is called non-alcoholic steatohepatitis (NASH).[1]
- One of the leading cause for cirrhosis in adults in united states is NASH. Almost 25 percent of adults with NASH may lead to cirrhosis.
- On the other hand, NASH progress to fibrosis that can lead to cirrhosis and hepatocellular cancer (HCC).[2]
- Rate of progression does not correlate with body mass index (BMI) or hyperlipidemia
Pathophysiology
- It is thought that pathophysiology of NAFLD is multifactorial that includes numerous genetic, dietary, metabolic and hormonal factors.
- Most experts believe that NAFLD is a 2 hit hypothesis.
- The first hit resulting in increased fat accumulation especially triglycerides within the hepatocyte and increases the risk of liver injury.
- On the second hit inflammatory cytokines causes mitochondrial dysfunction and oxidative stress which in turn lead to steatohepatitis and/or fibrosis.[3].
- Free fatty acids (FFA) play very crucial role in damaging the liver indirectly by either undergoing β-oxidation or are esterified with glycerol to form triglycerides, leading to hepatic fat accumulation.
- Now there is new evidence that FFA is directly causing the liver damage by increasing the oxidative stress by upregulation of TNF-alpha expression via a lysosomal pathway.
- Oxidative stress inhibits the replication process in the mature hepatocytes, Results in the proliferation of progenitor (oval ) cell population and later they differentiate into hepatocyte-like cells. Now both the oval and hepatocyte-like cells play a very important role in the process of fibrosis and hepatocellular carcinogenesis.[3]
- Alterations in MTP/apoB synthesis and secretion have been implicated as one of the potential mechanisms in the pathogenesis of NAFLD which in turn leads to a decreased capacity for lipid export
- Normally triglycerides are transported from the liver in the form of VLDL particles which are then formed by the incorporation of triglyceride into apolipoprotein B (apoB) by microsomal transfer protein (MTP).[5]
Risk Factors
- Common risk factors in the development of NAFLD is related to obesity which will result in insulin resistance and metabolic syndrome.[6][7]It is estimated that approximately 80% of the obese people suffer from NAFLD.[8]
- Patients who are having type 2 diabetes mellitus are more prone to develop Nafld[9][10]
- Less commonly Patients with hypertension and dyslipidemia are also associated with developing NAFLD
Other Common Causes are :
- Medications like Tamoxifen ,corticosteriods , methotrxate
- Viral Hepatitis.
- Rapid weight loss.
- Malnutrition.
Signs and Symptoms
Usually, NAFLD [Nonalcoholic fatty liver disease] presents with no or few symptoms and sighs but when it does it shows the following[11]
- Hepatomegaly
- Patient presents with fatigue
- Abdominal swelling (ascites)
- Enlarged breasts in men ( due to decreased estrogen clearance by liver damage )
- Pain in the upper right abdomen
- Yellowing of the skin and eyes (jaundice)
- Enlarged spleen (usually observed by a physician during physical exam)
PREVENTION
There are some ways to prevent NAFLD,
- Eating a healthy diet is the first and very important step.
- Exercise on regular basis.
- Maintain a healthy weight.
- Alcohol cessation, If Patient drinks.
- Take medications under the guidance of physician when needed,don't take unnecessary medications .
- ↑ "American Liver Foundation - Non-Alcoholic Fatty Liver Disease".
- ↑ "Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. - PubMed - NCBI".
- ↑ 3.0 3.1 Dowman JK, Tomlinson JW, Newsome PN (2010). "Pathogenesis of non-alcoholic fatty liver disease". QJM. 103 (2): 71–83. doi:10.1093/qjmed/hcp158. PMC 2810391. PMID 19914930.
- ↑ Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ (2004). "Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway". Hepatology. 40 (1): 185–94. doi:10.1002/hep.20283. PMID 15239102.
- ↑ "Apolipoprotein synthesis in nonalcoholic steatohepatitis - Charlton - 2002 - Hepatology - Wiley Online Library".
- ↑ "Nonalcoholic Fatty Liver Disease".
- ↑ Sung KC, Jeong WS, Wild SH, Byrne CD (2012). "Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes". Diabetes Care. 35 (4): 717–22. doi:10.2337/dc11-1853. PMC 3308286. PMID 22338098.
- ↑ "Nonalcoholic fatty liver disease".
- ↑ "Nonalcoholic Fatty Liver Disease".
- ↑ "Nonalcoholic Fatty Liver Disease & NASH | NIDDK".
- ↑ "Nafld".
Diagnosis
Incidental finding of Fatty liver on ultrasound | |||||||||||||||||||||||||||||||||||
Check for persistently raised LFTs | |||||||||||||||||||||||||||||||||||
Ask the patient for significant alcohol intake | |||||||||||||||||||||||||||||||||||
NO | YES | ||||||||||||||||||||||||||||||||||
Diagnose NAFLD | Consider other alcoholic related diseases | ||||||||||||||||||||||||||||||||||
Monitor severity of the disease
Offer Enhanced Liver Fibrosis Test (ELF) | |||||||||||||||||||||||
(>10.51) ELF Positive | (<10.51) ELF Negative | ||||||||||||||||||||||
Indicating advanced fibrosis and risk of progression to cirrhosis | Typically Benign -- Advanced fibrosis unlikely | ||||||||||||||||||||||
Refer the patient to Heptologist | |||||||||||||||||||||||
- On negative ELF test offer retest for every 3 years for adults and 2 years for children.